Inventor · disambiguated record
Dirk Nagorsen
Also filed as: NAGORSEN DIRK
11 granted patents·5 pending applications·78 citations·filing 2010–2021
89Inventor score
Top patents by PatentIndex Score
16 records- 0191US8840888B2Dosage regimen for administering a CD19XCD3 bispecific antibodyNAGORSEN DIRK·Filed 2010·Granted Sep 23, 2014·23 cites·34 claims
- 0290US9688760B2Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domainsAMGEN RES MUNICH GMBH·Filed 2014·Granted Jun 27, 2017·17 cites·10 claims
- 0389US11084876B2Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domainsAMGEN RES MUNICH GMBH·Filed 2017·Granted Aug 10, 2021·4 cites·14 claims
- 0489US10662243B2Dosage regimen for administering a CD19XCD3 bispecific antibodyAMGEN RES MUNICH GMBH·Filed 2014·Granted May 26, 2020·6 cites·20 claims
- 0584US10696744B2Means and methods for treating DLBCLAMGEN RES MUNICH GMBH·Filed 2015·Granted Jun 30, 2020·3 cites·13 claims
- 0684US10191034B2Dosage regimen for administrating a CD19×CD3 bispecific antibody to patients at risk for potential adverse effectsNAGORSEN DIRK·Filed 2012·Granted Jan 29, 2019·9 cites·20 claims
- 0781US9192665B2Means and methods for treating DLBCLZUGMAIER GERHARD·Filed 2011·Granted Nov 24, 2015·7 cites·19 claims
- 0879US10130638B2Prevention of adverse effects caused by CD3 specific binding domainsZUGMAIER GERHARD·Filed 2011·Granted Nov 20, 2018·5 cites·12 claims
- 0978US9486475B2PPS for the prevention of potential adverse effects caused by CD3 specific binding domainsAMGEN RES MUNICH GMBH·Filed 2014·Granted Nov 8, 2016·4 cites·14 claims
- 1058US11579142B2Dosage regimen for administering a CD19xCD3 bispecific antibody to patients at risk for potential adverse effectsAMGEN RES MUNICH GMBH·Filed 2018·Granted Feb 14, 2023·0 cites·11 claims
- 1158US2023398147A1Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancerAMGEN INC·Filed 2021·Application pending·0 cites
- 1253US11633408B2Prevention of adverse effects caused by CD3 specific binding domainsAMGEN RES MUNICH GMBH·Filed 2018·Granted Apr 25, 2023·0 cites·16 claims
- 1350US2023146593A1Method for treatment and prophylaxis of crs in patients comprising a combination of bispecific antibodies binding to cds x cancer cell and tnf alpha or il-6 inhibitorAMGEN INC·Filed 2021·Application pending·0 cites
- 1449US2021301017A1Prolonged administration of a bispecific antibody construct binding to cd33 and cd3AMGEN RES MUNICH GMBH·Filed 2019·Application pending·0 cites
- 1547US2024209085A1Adverse effects-mitigating administration of a bispecific construct binding to cd33 and cd3AMGEN INC·Filed 2021·Application pending·0 cites
- 1647US2022389099A1Methods for treating leukemiaAMGEN INC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Dirk Nagorsen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →